IndraLab

Statements

KCNA3 inhibits SHPK. 2 / 2
| 2
reach
"An early phase study of Kv1.3 channel-blocking ShK analog (ShK-186/dalazatide) in humans has demonstrated safety, supported by multiple pre-clinical studies showing safety and efficacy of Kv1.3 blockers in models of systemic autoimmunity, obesity, CNS demyelinating disorders, and neurodegeneration [15, 18, 28, 42–44], suggesting that rapid translation of Kv1.3 blockers to ischemic stroke is feasible [45]."
31153377
reach
"siRNA knockdown of KCNA3 reversed the inhibitory effects of ShK, rendering GAD65 specific T-cell proliferation and IFN-gamma responses unaffected by ShK (XREF_FIG)."
28248292